Chang T, Chen Y, Luo J, Zhang C, Chen S, Lin Z
Immunotargets Ther. 2025; 14:99-121.
PMID: 39990274
PMC: 11846490.
DOI: 10.2147/ITT.S492334.
Khashchenko E, Krechetova L, Vishnyakova P, Fatkhudinov T, Inviyaeva E, Vtorushina V
Cells. 2024; 13(14.
PMID: 39056769
PMC: 11274988.
DOI: 10.3390/cells13141187.
Yang R, Yang Y, Liu R, Wang Y, Yang R, He A
Front Immunol. 2024; 15:1414264.
PMID: 39007146
PMC: 11239349.
DOI: 10.3389/fimmu.2024.1414264.
Netskar H, Pfefferle A, Goodridge J, Sohlberg E, Dufva O, Teichmann S
Nat Immunol. 2024; 25(8):1445-1459.
PMID: 38956379
PMC: 11291284.
DOI: 10.1038/s41590-024-01884-z.
Padoan B, Casar C, Krause J, Schultheiss C, Baumdick M, Niehrs A
Cell Rep. 2024; 43(4):114089.
PMID: 38615318
PMC: 11416720.
DOI: 10.1016/j.celrep.2024.114089.
Feeder-free differentiation of human iPSCs into natural killer cells with cytotoxic potential against malignant brain rhabdoid tumor cells.
Kiran S, Xue Y, Sarker D, Li Y, Sang Q
Bioact Mater. 2024; 36:301-316.
PMID: 38496035
PMC: 10940949.
DOI: 10.1016/j.bioactmat.2024.02.031.
Natural killer cell therapies.
Vivier E, Rebuffet L, Narni-Mancinelli E, Cornen S, Igarashi R, Fantin V
Nature. 2024; 626(8000):727-736.
PMID: 38383621
DOI: 10.1038/s41586-023-06945-1.
models to study natural killer cell dynamics in the tumor microenvironment.
Carannante V, Wiklund M, Onfelt B
Front Immunol. 2023; 14:1135148.
PMID: 37457703
PMC: 10338882.
DOI: 10.3389/fimmu.2023.1135148.
NK cell defects: implication in acute myeloid leukemia.
DSilva S, Singh M, Pinto A
Front Immunol. 2023; 14:1112059.
PMID: 37228595
PMC: 10203541.
DOI: 10.3389/fimmu.2023.1112059.
The Human Milk Oligosaccharide 2'-Fucosyllactose Shows an Immune-Enhancing Effect in a Cyclophosphamide-Induced Mouse Model.
Jo S, Kim K, Park S, Paik H, Kim J
J Microbiol Biotechnol. 2023; 33(3):356-362.
PMID: 36697223
PMC: 10084749.
DOI: 10.4014/jmb.2211.11049.
The underappreciated role of resident epithelial cell populations in metastatic progression: contributions of the lung alveolar epithelium.
Christenson J, Williams M, Richer J
Am J Physiol Cell Physiol. 2022; 323(6):C1777-C1790.
PMID: 36252127
PMC: 9744653.
DOI: 10.1152/ajpcell.00181.2022.
Current Progress of CAR-NK Therapy in Cancer Treatment.
Pang Z, Wang Z, Li F, Feng C, Mu X
Cancers (Basel). 2022; 14(17).
PMID: 36077853
PMC: 9454439.
DOI: 10.3390/cancers14174318.
Natural killer cells and acute myeloid leukemia: promises and challenges.
Rahmani S, Yazdanpanah N, Rezaei N
Cancer Immunol Immunother. 2022; 71(12):2849-2867.
PMID: 35639116
PMC: 10991240.
DOI: 10.1007/s00262-022-03217-1.
Natural Killer Cell Membrane-Cloaked Virus-Mimicking Nanogenerator with NIR-Triggered Shape Reversal and •C/•OH Storm for Synergistic Thermodynamic-Chemodynamic Therapy.
Lin J, Li Y, Wang P, Wu M, Zhu F, Zhang Y
Adv Sci (Weinh). 2021; 9(5):e2103498.
PMID: 34923766
PMC: 8844581.
DOI: 10.1002/advs.202103498.
Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition).
Cossarizza A, Chang H, Radbruch A, Abrignani S, Addo R, Akdis M
Eur J Immunol. 2021; 51(12):2708-3145.
PMID: 34910301
PMC: 11115438.
DOI: 10.1002/eji.202170126.
Psychosocial stress and immunosuppression in cancer: what can we learn from new research?.
Singh A, Chatterjee U, MacDonald C, Repasky E, Halbreich U
BJPsych Adv. 2021; 27(3):187-197.
PMID: 34295535
PMC: 8294471.
DOI: 10.1192/bja.2021.9.
TREM2 promotes natural killer cell development in CD3CD122NK1.1 pNK cells.
Lee H, Lee E, Yi J, Ji K, Kim S, Choi H
BMC Immunol. 2021; 22(1):30.
PMID: 33980160
PMC: 8114489.
DOI: 10.1186/s12865-021-00420-0.
Human NK cells, their receptors and function.
Quatrini L, Della Chiesa M, Sivori S, Mingari M, Pende D, Moretta L
Eur J Immunol. 2021; 51(7):1566-1579.
PMID: 33899224
PMC: 9292411.
DOI: 10.1002/eji.202049028.
Mechanisms of Immune Evasion in Acute Lymphoblastic Leukemia.
Pastorczak A, Domka K, Fidyt K, Poprzeczko M, Firczuk M
Cancers (Basel). 2021; 13(7).
PMID: 33810515
PMC: 8037152.
DOI: 10.3390/cancers13071536.
Cytokine-Induced Memory-Like NK Cells with High Reactivity against Acute Leukemia Blasts and Solid Tumor Cells Suitable for Adoptive Immunotherapy Approaches.
Tanzi M, Consonni M, Falco M, Ferulli F, Montini E, Pasi A
Cancers (Basel). 2021; 13(7).
PMID: 33808051
PMC: 8036252.
DOI: 10.3390/cancers13071577.
